Messenger RNA electroporated hepatitis B virus (HBV) antigen-specific T cell receptor (TCR) redirected T cell therapy is well-tolerated in patients with recurrent HBV-related hepatocellular carcinoma post-liver transplantation: results from a phase I trial

Yang, Fan; Zheng, Xiaofang; Koh, Sarene; Lu, Jianxi; Cheng, Jintao; Li, Panlong; Du, Cong; Chen, Yunhao; Chen, Xiaoyan; Yang, Li; Chen, Wanxin; Wong, Regina Wanju; Wai, Lu-En; Wang, Tingting; Zhang, Qi; Chen, Wenjie

doi:10.1007/s12072-023-10524-x

Cited by 8 publications

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In two HCC patients who received HBV-specific TCR-T therapy, one patient showed a reduction in five of six lung metastases after one year of treatment [ 179 ]. Furthermore, two phase I clinical trials have also confirmed the safety and tolerability of HBV-specific TCR-T cell therapy [ 180 , 181 ]. With the advancement of high-throughput sequencing technology, the identification of neoantigen-specific T cells has become possible.…”

Section: Emerging Immunotherapiesmentioning

confidence: 99%

Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives

Shen,

Zhu,

Xie

et al. 2024

J Hematol Oncol

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a major health concern worldwide, with limited therapeutic options and poor prognosis. In recent years, immunotherapies such as immune checkpoint inhibitors (ICIs) have made great progress in the systemic treatment of HCC. The combination treatments based on ICIs have been the major trend in this area. Recently, dual immune checkpoint blockade with durvalumab plus tremelimumab has also emerged as an effective treatment for advanced HCC. However, the majority of HCC patients obtain limited benefits. Understanding the immunological rationale and exploring novel ways to improve the efficacy of immunotherapy has drawn much attention. In this review, we summarize the latest progress in this area, the ongoing clinical trials of immune-based combination therapies, as well as novel immunotherapy strategies such as chimeric antigen receptor T cells, personalized neoantigen vaccines, oncolytic viruses, and bispecific antibodies.

show abstract

Section: Emerging Immunotherapiesmentioning

confidence: 99%